Your payment is in progress...
  +1 (704) 266-3234

Global Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market

Published on: May 2020 | From USD $3950 | Published By: VERIFIED MARKET RESEARCH | Number Of Pages: 203

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market Size And Forecast
According To Verified Market Research, Global Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2019 to 2026.
Global Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market Outlook

Increasing research and development activities by pharmaceutical and biopharmaceutical companies to develop new products and novel treatment is the major driver responsible for the growth of the global ABSSSI market. For instance, in February 2019, Paratek Pharmaceuticals Inc., launched NUZYRA intravenous and oral antibiotics in the treatment of ABSSSI. Moreover, in 2018, Fresenius Kabi received US FDA approval for a new drug application of daptomycin. Besides, an increasing number of ambulatory patients seeking treatment for skin and skin structure infections will further be expected to fuel the market growth. However, the stringent regulatory policies by government bodies, patent expiration, and increasing incidence of resistant strains of causative agents are the factors that might hamper the market growth.

Global Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market Competitive Landscape
The Global Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market study report will provide valuable insight with an emphasis on the global market including some of the major players such as Glenmark Pharmaceuticals Ltd, Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd, Melinta Therapeutics, Inc., Sandoz Inc. (a subsidiary of Novartis), Paratek Pharmaceuticals, Inc., Allergan plc, Merck & Co., Inc., Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Ltd.), and Cadila Healthcare Ltd.

1 INTRODUCTION OF GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION (ABSSSI) MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION (ABSSSI) MARKET OUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION (ABSSSI) MARKET, BY ACTIVE INGREDIENT
5.1 Overview
5.2 Delafloxacin
5.3 Vancomycin
5.4 Oritavancin
5.5 Daptomycin
5.6 Others

6 GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION (ABSSSI) MARKET, BY ROUTE OF ADMINISTRATION
6.1 Overview
6.2 Oral
6.3 Parenteral
6.4 Topical

7 GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION (ABSSSI) MARKET, BY DISTRIBUTION CHANNEL
7.1 Overview
7.2 Hospital Pharmacies
7.3 Retail Pharmacies
7.4 Online Pharmacies

8 GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION (ABSSSI) MARKET, BY GEOGRAPHY
8.1 Overview
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Rest of the World
8.5.1 Latin America
8.5.2 Middle East

9 GLOBAL ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION (ABSSSI) MARKET COMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Glenmark Pharmaceuticals Ltd
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments

10.2 Fresenius SE & Co. KGaA
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments

10.3 Teva Pharmaceutical Industries Ltd
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments

10.4 Melinta Therapeutics, Inc.
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments

10.5 Sandoz Inc. (a subsidiary of Novartis)
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments

10.6 Paratek Pharmaceuticals, Inc.
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments

10.7 Allergan plc
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments

10.8 Merck & Co., Inc.
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments

10.9 Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Ltd.)
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Developments

10.10 Cadila Healthcare Ltd
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Developments

11 Appendix
11.1 Related Research

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Please Choose License Type

USD $3950
USD $4750
USD $6750
Offer

Why Us

  • Why Us In-depth database
    Our Report’s database covers almost all topics of all regions over the Globe..
  • Why Us Recognised publishing sources
    Tie ups with top publishers around the globe.
  • Why Us Customer Support
    Complete pre and post sales support.
  • Why Us Safe & Secure
    Complete secure payment process.